Search
TOP-1288
go.drugbank.com/drugs/DB14839InvestigationalTOP-1288 is under investigation in clinical trial NCT02888379 (Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
TAK-754
go.drugbank.com/drugs/DB17850InvestigationalDeveloped by Takeda, it is being investigated for the treatment of hemophilia A.[A259831]
Afimkibart
go.drugbank.com/drugs/DB18718InvestigationalIt is being investigated for ulcerative colitis.
Cimlanod
go.drugbank.com/drugs/DB14983InvestigationalCimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)
Xelaglifam
go.drugbank.com/drugs/DB21598InvestigationalXelaglifam is under investigation in clinical trial NCT04982705 (IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics). Xelaglifam has a monoisotopic molecular weight of 501.2 Da.
Managlinat dialanetil
go.drugbank.com/drugs/DB05518InvestigationalCS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
TD-2749
go.drugbank.com/drugs/DB05905ExperimentalTD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders
Nemtabrutinib
go.drugbank.com/drugs/DB18866InvestigationalNemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic
Maytansine
go.drugbank.com/drugs/DB19582InvestigationalMaytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients).
RD06-04
go.drugbank.com/drugs/DB24647InvestigationalRD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).